Our latest articles
Spero proves a canny dealmaker – again
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
Novartis has the most new approvals, but Lilly’s are worth more
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Intellia delivers a second knockdown success
Encouraging early results in hereditary angioedema join further progress in amyloidosis, but investors remain wary.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Akero’s imperfect Harmony
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Esmo 2022 – Regeneron stakes its Lag3 claim
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
